Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 805 across all filing types
Latest filing 2010-12-02 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
PHARMING AWARDED ‘BEST BIOTECHNOLOGY COMPANY’ BY THE WORLD TECHNOLOGY NETWORK
Regulatory Filings Classification · 95% confidence The document is a press release dated December 2, 2010, announcing that Pharming Group NV received an award ('Best Biotechnology Company' by the World Technology Network). It contains general company news, highlights of a recent product approval (Ruconest), and boilerplate 'About Us' information. This type of announcement, which is not a formal regulatory filing (like 10-K, IR, ER) but rather a general corporate update or news item, best fits the 'Regulatory Filings' (RNS) category as a miscellaneous announcement, or potentially a general 'Investor Presentation' (IP) if it were a presentation, but since it's a press release about an award, RNS is the most appropriate fallback for non-standard corporate news that isn't explicitly defined elsewhere. Given the options, it is not an ER (Earnings Release), 10-K (Annual Report), CT (Call Transcript), or a specific financial/governance report. It is a general corporate announcement/news release. RNS serves as the general regulatory/miscellaneous announcement category.
2010-12-02 English
PHARMING AWARDED ‘BEST BIOTECHNOLOGY COMPANY’ BY THE WORLD TECHNOLOGY NETWORK
Regulatory Filings Classification · 97% confidence The provided document text is extremely short (139 characters) and consists entirely of an error message indicating a processing failure ('status: failure', 'Error: antiword command not found'). This text does not contain any financial data, regulatory headers, or specific filing content that would allow classification into the defined categories (10-K, ER, IR, etc.). Since it is not a substantive financial document but rather a system error report, it cannot be classified according to the provided definitions. The most appropriate fallback category for an unclassifiable or miscellaneous system/error document that doesn't fit standard financial reporting is 'Regulatory Filings' (RNS), although this is a weak fit based on content, it serves as the required fallback for unclassifiable inputs.
2010-12-02 English
PHARMING ANNOUNCES TOPLINE STUDY RESULTS ON PROPHYLACTIC USE OF RUCONEST IN HEREDITARY ANGIOEDEMA
Regulatory Filings Classification · 96% confidence The document is a press release announcing topline study results for a drug (Ruconest) in treating Hereditary Angioedema (HAE). It details study design, efficacy data (attack rates), safety findings, and future plans. This type of announcement, focusing on clinical trial outcomes and product development updates, is typically classified as an Investor Presentation (IP) if it were a formal deck, or often falls under general Investor Relations material. Since it is a news release detailing clinical progress and product status, and it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific legal/governance document, it best fits the 'Investor Presentation' (IP) category, which often encompasses detailed updates shared with the investment community outside of mandatory financial reports. Given the detailed nature of the results announcement, IP is the most appropriate fit among the provided options, as it serves to inform investors about key operational/clinical milestones.
2010-11-29 English
PHARMING ANNOUNCES TOPLINE STUDY RESULTS ON PROPHYLACTIC USE OF RUCONEST IN HEREDITARY ANGIOEDEMA
Regulatory Filings
2010-11-29 English
Pharming's Ruconest For Hae Granted European Marketing Authorization
Regulatory Filings Classification · 95% confidence The document is a press release dated October 28, 2010, announcing that Pharming's product Ruconest has been granted European Marketing Authorization. It details the significance of the approval, includes quotes from CEOs, provides background on the drug and the disease, and crucially, announces a conference call for the next day (October 29) to discuss the approval. This format—a news announcement about a significant corporate event (product approval/milestone payment) coupled with an invitation to a conference call—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full financial report (10-K, IR) or a transcript of the call itself (CT), and it focuses on the immediate financial/operational impact of the approval, it best fits the 'Earnings Release' category, which often covers major operational milestones that impact results, or the general 'Regulatory Filings' (RNS) if it were less focused on immediate financial context. Given the structure announcing a major event and scheduling a follow-up call, ER is a strong candidate, but since it is not explicitly reporting quarterly/periodical financial results (it's a regulatory approval announcement), RNS (Regulatory Filings) is the most appropriate fallback for a significant, non-standard announcement. However, many companies use ER templates for major operational news that drives future earnings. Given the context of a major product approval and milestone payment, it functions similarly to an earnings announcement regarding operational success. I will classify it as RNS as it is a regulatory/approval announcement that doesn't fit the specific financial report types.
2010-10-29 English
Pharming announces nine month financial report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the nine-month period ended September 30, 2010, for Pharming Group NV. It includes detailed financial highlights, operational updates, management commentary, and full consolidated financial statements (Statement of Financial Position and Statement of Income). It is not a mere announcement (RPA) because it contains substantive financial data and analysis for an interim period. Therefore, it is classified as an Interim/Quarterly Report. 9M 2010
2010-10-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.